Evidence map›Paper›PMID 26609171›Full record

ArticleThe Journal of nutrition2016

Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells.

Ornella I Selmin, Changming Fang, Adam M Lyon, Tom C Doetschman, Patricia A Thompson, Jesse D Martinez, Jeffrey W Smith, Peter M Lance, Donato F Romagnolo

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of nutrition, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Pleiotropic roles of FXR in liver and colorectal cancers.Molecular and cellular endocrinology · 2022
    Article
  13. Review
  14. Review
  15. International journal of molecular sciences · 2021
    Article
  16. Review
  17. Review
  18. Article
  19. AInternational journal of molecular sciences · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ornella I SelminDepartment of Nutritional Sciences and University of Arizona Cancer Center, University of Arizona, Tucson, AZ; and.
Changming FangUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ; and.
Adam M LyonDepartment of Nutritional Sciences and.
Tom C DoetschmanUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ; and.
Patricia A ThompsonUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ; and.
Jesse D MartinezUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ; and.
Jeffrey W SmithSanford/Burnham Medical Research Institute, Cancer Center Division, La Jolla, CA.
Peter M LanceUniversity of Arizona Cancer Center, University of Arizona, Tucson, AZ; and.
Donato F RomagnoloDepartment of Nutritional Sciences and University of Arizona Cancer Center, University of Arizona, Tucson, AZ; and donato@u.arizona.edu.
University of Arizona · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2M
NCI NIH HHS P30 CA023074NCI NIH HHS P30CA23074
6 · The paper itself

Abstract

backgroundThe farnesoid X receptor (FXR) regulates bile acid (BA) metabolism and possesses tumor suppressor functions. FXR expression is reduced in colorectal tumors of subjects carrying inactivated adenomatous polyposis coli (APC). Identifying the mechanisms responsible for this reduction may offer new molecular targets for colon cancer prevention.

objectiveWe investigated how APC inactivation influences the regulation of FXR expression in colonic mucosal cells. We hypothesized that APC inactivation would epigenetically repress nuclear receptor subfamily 1, group H, member 4 (FXR gene name) expression through increased CpG methylation.

methodsNormal proximal colonic mucosa and normal-appearing adjacent colonic mucosa and colon tumors were collected from wild-type C57BL/6J and Apc-deficient (Apc(Min) (/+)) male mice, respectively. The expression of Fxr, ileal bile acid-binding protein (Ibabp), small heterodimer partner (Shp), and cyclooxygenase-2 (Cox-2) were determined by real-time polymerase chain reaction. In both normal and adjacent colonic mucosa and colon tumors, we measured CpG methylation of Fxr in bisulfonated genomic DNA. In vitro, we measured the impact of APC inactivation and deoxycholic acid (DCA) treatment on FXR expression in human colon cancer HCT-116 cells transfected with silencing RNA for APC and HT-29 cells carrying inactivated APC.

resultsIn Apc(Min) (/+) mice, constitutive CpG methylation of the Fxrα3/4 promoter was linked to reduced (60-90%) baseline Fxr, Ibabp, and Shp and increased Cox-2 expression in apparently normal adjacent mucosa and colon tumors. Apc knockdown in HCT-116 cells increased cellular myelocytomatosis (c-MYC) and lowered (∼50%) FXR expression, which was further reduced (∼80%) by DCA. In human HCT-116 but not HT-29 colon cancer cells, DCA induced FXR expression and lowered CpG methylation of FXR.

conclusionsWe conclude that the loss of APC function favors the silencing of FXR expression through CpG hypermethylation in mouse colonic mucosa and human colon cells, leading to reduced expression of downstream targets (SHP, IBABP) involved in BA homeostasis while increasing the expression of factors (COX-2, c-MYC) that contribute to inflammation and colon cancer.

Indexed as

DNA MethylationGenes, APCGene SilencingAdenocarcinomaAdenomatous Polyposis ColiAnimalsBile Acids and SaltsColonColonic NeoplasmsCyclooxygenase 2Gene ExpressionHCT116 CellsHT29 CellsHumansMice, Inbred C57BLPromoter Regions, GeneticBile Acids and SaltsCyclooxygenase 2MYC protein, humannuclear receptor subfamily 0, group B, member 2Proto-Oncogene Proteins c-mycReceptor, Farnesoid X-ActivatedReceptors, Cytoplasmic and Nuclearadenomatous polyposis colibile acid metabolismcolon cancerCpG methylationdeoxycholic acidepigeneticsfarnesoid X receptorinflammation

Identifiers

PMID26609171
PMCPMC6636391
OpenAlexW2178161066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.